In summary, the tetracycline-controlled expression models for pancreatic cancer have been instrumental for the identification of cellular processes and molecular pathways by which a subset of cancer cells can escape a targeted ablation of KRAS and its downstream effector c-MYC. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.